<?xml version="1.0" encoding="UTF-8"?>
<p id="Par54">There is proof that fibrinolytic therapy in acute lung injury and ARDS progresss to survival [
 <xref ref-type="bibr" rid="CR69">69</xref>]. Anticoagulant therapy chiefly with low molecular weight heparin seems to improve prognosis in severe COVID-19 patients suffering from hypercoagulation status or with increased D-dimer [
 <xref ref-type="bibr" rid="CR105">105</xref>].
</p>
